Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Umeclidinium cost effective for COPD in UK

Umeclidinium cost effective for COPD in UK PharmacoEconomics & Outcomes News 804, p36 - 2 Jun 2018 Umeclidinium cost effective for COPD in UK Once-daily umeclidinium (UMEC) monotherapy appears to be cost effective for the treatment of chronic obstructive pulmonary disease (COPD) in the UK, according to findings of a GlaxoSmithKline (GSK)- funded study published in Cost Effectiveness and Resource Allocation. The GALAXY COPD disease progression model, populated with data from two 12-week head-to-head GSK trials in patients aged ≥40 years, was used to evaluate the cost effectiveness of umeclidinium compared with tiotropium (TIO) and glycopyrrolate (glycopyrronium; GLY) in patients with COPD, from a UK National Health Service (NHS) perspective over a lifetime time horizon. All drugs were administered once- daily via dry powder inhalers (ELIPTA, Handihaler and Breezhaler, respectively). Umeclidinium was estimated to increase life-years (LYs) and QALYs compared with tiotropium (+0.195 and +0.118, respectively), reduce the number of annual exacerbations (–0.053), and achieve incremental cost savings of £460 per patient. Umeclidinium was therefore dominant compared with tiotropium (more effective and less costly). Umeclidinium was estimated to increase LYs and QALYs compared with glycopyrrolate (+0.124 and +0.101, respectively), and reduce the number of annual exacerbations (–0.033), at an additional cost of £132 per patient, resulting http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics & Outcomes News Springer Journals

Umeclidinium cost effective for COPD in UK

PharmacoEconomics & Outcomes News , Volume 804 (1) – Jun 2, 2018

Umeclidinium cost effective for COPD in UK

Abstract

PharmacoEconomics & Outcomes News 804, p36 - 2 Jun 2018 Umeclidinium cost effective for COPD in UK Once-daily umeclidinium (UMEC) monotherapy appears to be cost effective for the treatment of chronic obstructive pulmonary disease (COPD) in the UK, according to findings of a GlaxoSmithKline (GSK)- funded study published in Cost Effectiveness and Resource Allocation. The GALAXY COPD disease progression model, populated with data from two 12-week head-to-head GSK trials in patients aged...
Loading next page...
 
/lp/springer_journal/umeclidinium-cost-effective-for-copd-in-uk-4vRfoztll9
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
ISSN
1173-5503
eISSN
1179-2043
DOI
10.1007/s40274-018-5000-5
Publisher site
See Article on Publisher Site

Abstract

PharmacoEconomics & Outcomes News 804, p36 - 2 Jun 2018 Umeclidinium cost effective for COPD in UK Once-daily umeclidinium (UMEC) monotherapy appears to be cost effective for the treatment of chronic obstructive pulmonary disease (COPD) in the UK, according to findings of a GlaxoSmithKline (GSK)- funded study published in Cost Effectiveness and Resource Allocation. The GALAXY COPD disease progression model, populated with data from two 12-week head-to-head GSK trials in patients aged ≥40 years, was used to evaluate the cost effectiveness of umeclidinium compared with tiotropium (TIO) and glycopyrrolate (glycopyrronium; GLY) in patients with COPD, from a UK National Health Service (NHS) perspective over a lifetime time horizon. All drugs were administered once- daily via dry powder inhalers (ELIPTA, Handihaler and Breezhaler, respectively). Umeclidinium was estimated to increase life-years (LYs) and QALYs compared with tiotropium (+0.195 and +0.118, respectively), reduce the number of annual exacerbations (–0.053), and achieve incremental cost savings of £460 per patient. Umeclidinium was therefore dominant compared with tiotropium (more effective and less costly). Umeclidinium was estimated to increase LYs and QALYs compared with glycopyrrolate (+0.124 and +0.101, respectively), and reduce the number of annual exacerbations (–0.033), at an additional cost of £132 per patient, resulting

Journal

PharmacoEconomics & Outcomes NewsSpringer Journals

Published: Jun 2, 2018

There are no references for this article.